What are high-risk medications in insurance claims?
Understanding which medications require heightened monitoring, managing risks in insurance claims, and building protocols to safeguard claimants.
Published: 3 April 2026 | Updated: 3 April 2026
Defining High-Risk Medications
High-risk medications are drugs with significant potential to cause serious harm if not used appropriately. In the insurance context, "high-risk" encompasses medications that commonly cause adverse events in claims populations, medications with high addiction or dependence potential, medications that require specific monitoring, or medications that interact dangerously with substances common to claimant populations.
For insurers, identifying high-risk medications is essential for several reasons. These medications demand intensified monitoring and oversight. They require careful prescriber communication and explicit approval before funding. They often need regular clinical review to ensure continued appropriateness. They carry liability implications if harm occurs. Most importantly, managing them well prevents preventable harm to claimants.
Categories of High-Risk Medications
Opioid Analgesics
Opioids top the high-risk list in insurance claims. They're essential for severe acute pain but carry risks of dependence, respiratory depression, overdose (especially when combined with benzodiazepines or alcohol), and paradoxical pain amplification with chronic use. In workers compensation and CTP claims, opioid use beyond 8-12 weeks post-injury is particularly concerning because evidence shows worse outcomes with chronic opioid therapy than with non-opioid pain management.
Specific monitoring for opioids should include: dose review at 4-week intervals, documented rationale for any dose escalations, screening for concurrent benzodiazepine use (which increases overdose risk), and explicit discussion about when opioids should be ceased or de-escalated. Multiple opioid prescribers or refills from multiple pharmacies warrant rapid intervention.
Benzodiazepines
Benzodiazepines (sedatives used for anxiety, insomnia, muscle spasms) pose high dependence risk, particularly with chronic use. They're dangerous when combined with opioids (significantly increasing respiratory depression and overdose risk) or alcohol. In older claimants, they increase falls and fracture risk. Despite these risks, they're commonly prescribed in insurance claims because they provide immediate symptom relief.
For benzodiazepines, protocols should specify: use limited to short-term, acute situations (typically 2-4 weeks); explicit review at the 4-week mark with transition to non-benzodiazepine management; screening for concurrent opioid or alcohol use before prescribing; and increased monitoring in claimants over 65.
Antipsychotic Medications
Antipsychotic medications, while essential for psychotic disorders, carry risks of metabolic syndrome (weight gain, diabetes, lipid abnormalities), movement disorders, and sudden cardiac death, particularly in older patients. In insurance claims, they're sometimes prescribed off-label for anxiety or depression without clear indication, increasing risk without clear benefit.
Antipsychotics warrant monitoring for metabolic parameters, movement side effects, and continued appropriateness of indication. Use should be limited to documented psychotic disorders or severe psychiatric conditions where evidence supports their use.
High-Dose NSAIDs
Non-steroidal anti-inflammatory drugs, commonly used for pain, carry risks of gastrointestinal bleeding, cardiovascular events, and kidney damage, particularly in older claimants or those with pre-existing conditions. High-dose or prolonged NSAID use multiplies these risks. In combination with other drugs (including some pain medications), the risks escalate further.
NSAID monitoring should include: assessment of cardiovascular and kidney function before initiation, use at the lowest effective dose, limited duration (preferably not beyond 8-12 weeks), and regular screening for symptoms of bleeding, cardiovascular events, or kidney dysfunction.
Anticholinergic Medications
Medications with anticholinergic effects (including certain pain medications, psychiatric medications, and incontinence medications) increase risks of cognitive impairment, delirium, urinary retention, and falls. In older claimants, they're particularly risky. Multiple anticholinergic medications create cumulative risk.
Monitoring includes: assessment of cumulative anticholinergic burden (some medications aren't obviously anticholinergic but contribute to this burden), particular caution in claimants over 65, and consideration of alternatives with lower anticholinergic effects.
Medications Requiring Blood Test Monitoring
Some medications require regular blood tests to monitor for toxicity or effectiveness. These include lithium (which requires kidney function monitoring and serum level testing), warfarin (which requires INR monitoring), certain seizure medications, and others. In insurance claims, these medications demand organised protocols ensuring monitoring occurs on schedule.
| High-Risk Category | Key Concerns | Essential Monitoring |
|---|---|---|
| Opioids | Dependence, overdose, respiratory depression, paradoxical pain amplification | Dose review every 4 weeks, screening for concurrent sedative use, de-escalation planning |
| Benzodiazepines | Dependence, falls, respiratory depression when combined with opioids | Use limited to 2-4 weeks, review at 4 weeks, screening for concurrent opioids |
| Antipsychotics | Metabolic syndrome, movement disorders, cardiac risks | Metabolic monitoring, movement assessments, appropriateness of indication |
| High-dose NSAIDs | GI bleeding, cardiovascular events, kidney damage | Baseline kidney and cardiovascular assessment, monitoring for bleeding, limited duration |
| Anticholinergic agents | Cognitive impairment, delirium, falls | Cumulative burden assessment, caution in older claimants, regular review |
How to Identify High-Risk Medications in Your Claims
Red Flags for High-Risk Medication Use
- Long-term opioid use beyond 12 weeks post-injury without explicit de-escalation plan
- Concurrent opioid and benzodiazepine use without documented risk mitigation
- Benzodiazepine use extending beyond 4 weeks without transition to alternative management
- Antipsychotic prescribed for anxiety or insomnia without documented psychotic diagnosis
- High-dose NSAIDs in claimants over 65 or with kidney or cardiovascular disease
- Multiple prescribers prescribing the same high-risk medication (e.g., two prescribers each prescribing benzodiazepines)
- Medications requiring monitoring (lithium, warfarin) without documented recent monitoring
- Claimant on opioid plus benzodiazepine without documented communication about interaction risks
- Off-label use of high-risk medications without clear clinical indication and documented justification
Building a High-Risk Medication Protocol
1. Identification
Create a list of high-risk medications relevant to your claim populations. In workers compensation, opioids and benzodiazepines dominate. In NDIS, antipsychotics and seizure medications are more prevalent. In CTP, opioids and psychiatric medications are frequent. Your protocol should flag these medications for intensified review.
2. Pre-Approval Requirements
For high-risk medications, consider requiring pre-approval before your scheme funds the medication. The prescriber must provide clinical justification: Why is this medication necessary? What alternatives were considered and rejected? What monitoring plan is in place? What is the intended duration? This conversation happens upfront, preventing inappropriate use.
3. Regular Review Schedule
High-risk medications warrant more frequent review than standard medications. A claimant on opioids should have a medication review at 4 weeks, again at 8 weeks, and then regularly every 8-12 weeks thereafter. A claimant on benzodiazepines should be reviewed every 2-4 weeks to ensure the short-term duration is maintained. Regular review prevents drift into inappropriate chronic use.
4. Monitoring Requirements
Specify what monitoring is necessary for each high-risk medication. Opioids require pain scores and functional improvement assessment. Benzodiazepines require screening for dependence symptoms and transition planning. Medications requiring blood tests require documented monitoring dates. Your protocol makes monitoring expectations explicit.
5. Drug Interaction Screening
Particularly for opioids and benzodiazepines, screen for dangerous combinations. Opioids combined with alcohol, benzodiazepines, or other respiratory depressants require explicit risk discussion and enhanced monitoring. Screening should occur at medication initiation and at each review.
6. De-escalation and Cessation Planning
For high-risk medications intended for acute use (like benzodiazepines), document the plan for transitioning away from the medication. When will tapering occur? What alternative management will replace the medication? Explicit planning prevents indefinite continuation of high-risk drugs.
Communication with Prescribers
Your approach to high-risk medications should be collaborative. Rather than denying funding for a high-risk medication, open dialogue: "I see you've prescribed opioids for post-injury pain. Help me understand the expected duration and any thoughts about non-opioid options." This conversation educates, gathers information, and typically results in more appropriate prescribing.
When you identify concerning patterns (like a claimant on high-dose opioids at six months post-injury), raise it respectfully: "The research suggests opioid outcomes are best when they're used short-term and tapered by 8-12 weeks. What's your thinking on the continued dose here?" This opens dialogue and often leads to mutually beneficial changes.
Key Takeaways for Insurers
- High-risk medications carry significant potential for serious harm
- Key categories include opioids, benzodiazepines, antipsychotics, NSAIDs, and anticholinergics
- Each category requires specific monitoring and management protocols
- Early identification allows intervention before problems develop
- Pre-approval requirements and regular review ensure appropriate use
- De-escalation planning prevents indefinite use of acute-phase medications
- Collaborative communication with prescribers improves outcomes and relationship building
- Medication review identifies high-risk medication patterns and enables targeted intervention
Are Your High-Risk Medications Monitored Appropriately?
High-risk medications demand systematic monitoring to ensure they're appropriate, safe, and being de-escalated when no longer necessary. IMM's medication reviews identify high-risk patterns, assess appropriateness, and recommend monitoring protocols that protect claimants while managing your scheme's liability. For complex claims, high-risk medication oversight is a critical component of claims management.
Request a Medication Review
